Your Guide to Spravato® at iChange NJ

Esketamine, marketed under the brand name SPRAVATO®, has two FDA-approved indications. According to the package insert for SPRAVATO®, esketamine is indicated, along with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults and for managing depressive symptoms in adults with major depressive disorder (MDD) experiencing acute suicidal ideation (SI) or behavior.

The treatment recommended for treatment-resistant depression with esketamine, commercially known as Spravato, involves sessions twice per week for four weeks, followed by weekly treatments for an additional four weeks. During these treatment sessions, patients are monitored and supervised in the facility for 2 hours and must arrange for a documented safe ride home. It is important to note that patients cannot drive until they have had a full night's rest.

1. No liquids 30 minutes before the administration of esketamine (Spravato). 

2. No food for 2 hours prior to the administration of Spravato to ensure optimal results in treating treatment-resistant depression. 

3. Avoid the use of any nasal decongestant spray or steroid. 

4. Patients should refrain from operating machinery or vehicles until they have had a good night's rest; it may be advisable for them to have someone accompany them upon discharge.

If you have any questions or concerns about our esketamine treatment options, including Spravato for treatment-resistant depression, don't hesitate to contact us. Our friendly staff are always here to help. You can reach us via phone, email, or by filling out our online contact form.